Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy

Christine M. Barnett, Jason F. Flamiatos, Tomasz (Tom) Beer

    Research output: Contribution to journalArticle

    Abstract

    Sensitivity to androgen suppression therapy (AST) is a key determinant of survival in patients with nonlocalized prostate cancer. While an incomplete response to AST is associated with poor survival, additional therapy is typically withheld until obvious cancer progression. It is not known if the application of additional therapy earlier can have a favorable impact on long-term outcomes. We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy.

    Original languageEnglish (US)
    Pages (from-to)973-974
    Number of pages2
    JournalAnticancer Research
    Volume31
    Issue number3
    StatePublished - Mar 2011

    Fingerprint

    docetaxel
    Androgens
    Prostatic Neoplasms
    Recurrence
    Therapeutics
    Survival

    Keywords

    • Biochemical relapse
    • Chemotherapy
    • Docetaxel
    • Prostate cancer

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    @article{5083e1397c0d4a6f807f0152f706e784,
    title = "Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy",
    abstract = "Sensitivity to androgen suppression therapy (AST) is a key determinant of survival in patients with nonlocalized prostate cancer. While an incomplete response to AST is associated with poor survival, additional therapy is typically withheld until obvious cancer progression. It is not known if the application of additional therapy earlier can have a favorable impact on long-term outcomes. We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy.",
    keywords = "Biochemical relapse, Chemotherapy, Docetaxel, Prostate cancer",
    author = "Barnett, {Christine M.} and Flamiatos, {Jason F.} and Beer, {Tomasz (Tom)}",
    year = "2011",
    month = "3",
    language = "English (US)",
    volume = "31",
    pages = "973--974",
    journal = "Anticancer Research",
    issn = "0250-7005",
    publisher = "International Institute of Anticancer Research",
    number = "3",

    }

    TY - JOUR

    T1 - Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy

    AU - Barnett, Christine M.

    AU - Flamiatos, Jason F.

    AU - Beer, Tomasz (Tom)

    PY - 2011/3

    Y1 - 2011/3

    N2 - Sensitivity to androgen suppression therapy (AST) is a key determinant of survival in patients with nonlocalized prostate cancer. While an incomplete response to AST is associated with poor survival, additional therapy is typically withheld until obvious cancer progression. It is not known if the application of additional therapy earlier can have a favorable impact on long-term outcomes. We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy.

    AB - Sensitivity to androgen suppression therapy (AST) is a key determinant of survival in patients with nonlocalized prostate cancer. While an incomplete response to AST is associated with poor survival, additional therapy is typically withheld until obvious cancer progression. It is not known if the application of additional therapy earlier can have a favorable impact on long-term outcomes. We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy.

    KW - Biochemical relapse

    KW - Chemotherapy

    KW - Docetaxel

    KW - Prostate cancer

    UR - http://www.scopus.com/inward/record.url?scp=79956070910&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79956070910&partnerID=8YFLogxK

    M3 - Article

    C2 - 21498723

    AN - SCOPUS:79956070910

    VL - 31

    SP - 973

    EP - 974

    JO - Anticancer Research

    JF - Anticancer Research

    SN - 0250-7005

    IS - 3

    ER -